Water Operators Enabled to Cut CO2e Emissions by 2.8 Million Metric Tons, Using Xylem Technology
15.5.2023 14:30:00 EEST | Business Wire | Press release
Global water technology company Xylem (NYSE: XYL) delivered significant progress towards its Sustainability Goals in 2022, including enabling water utilities to reduce their CO2e emissions by 2.8 million metric tons since 2019. Through its operations, supplier and sector-wide partnerships, and green finance offerings, Xylem aims to advance water security by reducing greenhouse gas (GHG) emissions, building watershed stewardship and resilience to climate change, and advancing equitable access to Water, Sanitation and Hygiene (WASH).
The results, captured in Xylem’s latest Sustainability Report, saw the company achieve its 2025 CO2e emissions reduction goal well ahead of schedule. The reduction was enabled by the deployment of high-efficiency technologies and digital solutions. Xylem also made notable progress in reducing its own emissions, with Scope 1 and Scope 2 emissions down 21% year-on-year, while also continuing to make strides on water and waste footprint reductions across its operations.
“The stakes have never been higher in our work to tackle the world’s water challenges,” Patrick Decker, President and CEO of Xylem, said. “As impacts from climate change intensify, water operators in utilities and businesses are leaning in to be part of the solution – embracing advanced technologies that improve the resiliency and sustainability of water systems at an affordable cost – all while lowering carbon emissions.”
“Our latest Sustainability Report captures the impact of this team effort. In partnership with our customers and communities, we are working towards making the water sector a leader in climate change mitigation while solving the world’s toughest water challenges,” Decker added.
With 2022 marking another record-setting year of severe weather events, Xylem also expanded its humanitarian support. As part of the Xylem Watermark program, employees volunteered 157,000 hours to address water, sustainability, and community challenges, an increase of 39% on 2021. The program’s initiatives included providing vital aid to communities in Ukraine and to earthquake-affected regions of Turkey.
“In 2022, we were proud to partner with our customers to support their exceptional strides towards creating more modern, resilient, and environmentally sensitive water systems,” said Claudia Toussaint, Xylem’s Chief People and Sustainability Officer. “The vision of our customers and the ingenuity and diversity of our teams have been instrumental in achieving these results. It allows us to look to the future with renewed optimism and ambition.”
Other key highlights detailed in the Sustainability Report include:
- Executed a $1 billion credit facility that ties fees and interest rates to sustainability-related performance indicators, including emissions reduction.
- Reduced total process water use by 26% since 2019 and moved 12 of its 22 major facilities to 100% process water recycling and reuse.
- 88% of the electricity used at Xylem manufacturing, office, and service facilities came from renewable sources in 2022, an increase of 13% from 2021.
- Onboarded over 600 suppliers to the WASH4Work pledge and included supply partners in community WASH projects since 2019.
- Leveraged Xylem technology, solutions, and partnerships to mobilize aid for 30 areas impacted by disaster.
- Provided WASH solutions to communities in need, reaching more than 2.4 million people.
- Engaged 11,800 students through Xylem Ignite, the company’s youth program, with events including the Global Student Innovation Challenge, regional hackathons, and a six-month Innovation Incubator.
To learn more about Xylem’s sustainability progress, download the 2022 Sustainability Report.
*Refers to cars powered by internal combustion engine.
About Xylem
Xylem (XYL) is a leading global water technology company committed to solving critical water and infrastructure challenges with innovation. Our more than 17,000 diverse employees delivered revenue of $5.5 billion in 2022. We are creating a more sustainable world by enabling our customers to optimize water and resource management, and helping communities in more than 150 countries become water-secure. Join us at www.xylem.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230515005421/en/
Contact information
Houston Spencer
+1 (914) 240-3046
Houston.Spencer@xylem.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
